Almost Half of European and US Pharmaceuticals Companies Struggle to Use Data Insight
John E. Kaye
- Published
- Home, Technology

Inability to generate and use insights undermines competitiveness at 48% of drug companies surveyed
Nearly half of pharmaceutical companies (48%) admit their competitiveness is suffering because they cannot extract or use insights from data they already have within their business. An equal percentage (48%) admit they do not use their own data for business decisions as well as they could.
The findings are from research among 300 senior decision-makers within the pharmaceutical industry in the UK, US, Germany, France, Spain and Sweden, conducted by Aspen Technology, a global leader in asset optimisation software.
The research also reveals how poor digital capabilities hit business performance. Almost half (49%) say their companies struggle to use data effectively to improve time to market.
“This should sound an alarm bell within the pharmaceutical industry,” said David Leitham, Senior Vice President and General Manager Pharma, AspenTech. “Leading organisations stand out for their ability to use data effectively across all aspects of drug manufacture. Data-driven organisations are faster to innovate and respond to opportunities or threats at speed.”
The research also found a widespread lack of predictive capabilities within the industry. Almost half (49%) of respondents say their companies are not good enough at predicting demand for a product and adjusting output to match it. And almost as many (48%) rate their organisation as either poor or ineffective at using data to predict and resolve supply shortages.
Companies that have a more advanced digital culture use data effectively across all aspects of drug manufacture. More than three-quarters (78%) of such “digital culture leaders” in the research describe themselves as effective at using data to predict product demand and to forecast and resolve supply shortages.
“Pharma manufacturers have traditionally been moving slowly and incrementally towards ‘Pharma 4.0’,” said Leitham. “For more than half of all organisations this needs to accelerate if they are to avoid falling further behind.”
Further information
TOP STORIES
-
Trump threatens 'immediate 100pc tariffs' on European countries over tech taxes -
Home routers named ‘Europe’s forgotten internet security risk’ -
AI lab says brain-like engine could slash chatbot bills by 98 per cent -
The board challenge: why security is no longer an IT problem -
The fist-bumping, selfie-taking humanoid guide that could usher sightseeing tours into the AI age -
EU says ‘time for change’ on child social media safety after survey links platforms to youth distress -
UK’s under-16s social media ban risks giving parents false comfort, experts warn -
Redefining optical gas detection: how Optronics Group is building the future of industrial safety -
Claude maker Anthropic valued at nearly $1tn after record AI funding round -
NASA to send rabbit-like drones to scout site for first Moon base -
Apollo, Artemis, Ali and Live Aid satellite station set for new Moon role in £37m deal -
Four forces reshaping cyber risk in 2026 -
Siemens expands rail technology arm with Italian deal -
Italy draws global tech investors as Europe races to build its own champions -
Opel turns to Chinese EV technology for new European-built SUV -
Japan and Luxembourg deepen space ties as lunar race gathers pace -
Polymorphic attacks: the shape-shifting threat -
‘Lost’ zip design could give space exploration a lift -
Orbitae - AI by SDG Group launches Gena Suite to scale enterprise AI -
Firms ‘wasting AI’ by using it to speed up bad habits -
Why leadership matters when implementing AI -
Stratospheric telecoms blimp completes “historic” record 12-day flight over Atlantic -
Mobile operators warn of higher bills and slower 5G rollout after energy support exclusion -
The 2026 European awards cement Steve Durbin and the ISF at the forefront of cybersecurity -
These are the 10 AI trends to watch in 2026 that will drive business forward
Almost Half of European and US Pharmaceuticals Companies Struggle to Use Data Insight
John E. Kaye
- Published
- Home, Technology

TOP STORIES
-
Trump threatens 'immediate 100pc tariffs' on European countries over tech taxes -
Home routers named ‘Europe’s forgotten internet security risk’ -
AI lab says brain-like engine could slash chatbot bills by 98 per cent -
The board challenge: why security is no longer an IT problem -
The fist-bumping, selfie-taking humanoid guide that could usher sightseeing tours into the AI age -
EU says ‘time for change’ on child social media safety after survey links platforms to youth distress -
UK’s under-16s social media ban risks giving parents false comfort, experts warn -
Redefining optical gas detection: how Optronics Group is building the future of industrial safety -
Claude maker Anthropic valued at nearly $1tn after record AI funding round -
NASA to send rabbit-like drones to scout site for first Moon base -
Apollo, Artemis, Ali and Live Aid satellite station set for new Moon role in £37m deal -
Four forces reshaping cyber risk in 2026 -
Siemens expands rail technology arm with Italian deal -
Italy draws global tech investors as Europe races to build its own champions -
Opel turns to Chinese EV technology for new European-built SUV -
Japan and Luxembourg deepen space ties as lunar race gathers pace -
Polymorphic attacks: the shape-shifting threat -
‘Lost’ zip design could give space exploration a lift -
Orbitae - AI by SDG Group launches Gena Suite to scale enterprise AI -
Firms ‘wasting AI’ by using it to speed up bad habits -
Why leadership matters when implementing AI -
Stratospheric telecoms blimp completes “historic” record 12-day flight over Atlantic -
Mobile operators warn of higher bills and slower 5G rollout after energy support exclusion -
The 2026 European awards cement Steve Durbin and the ISF at the forefront of cybersecurity -
These are the 10 AI trends to watch in 2026 that will drive business forward


























